期刊文献+

病毒性肝炎后肝硬化合并胸腔积液150例临床分析 被引量:2

暂未订购
导出
摘要 目的:探讨肝硬化并发肝性胸腔积液的临床表现、发生机制及治疗。方法:对150例肝性胸腔积液患者的临床治疗进行回顾性分析。结果:本组150例肝性胸腔积液患者中,经综合治疗后124例(82.6%)胸腔积液完全消退,26例(17.4%)胸腔积液明显减少。结论:肝性胸腔积液是肝硬化较少见的并发症,是多因素作用的结果,采取多种方法综合治疗可改善预后。
作者 陈晖
出处 《中国医药导报》 CAS 2009年第21期151-151,155,共2页 China Medical Herald
  • 相关文献

参考文献6

二级参考文献24

  • 1米贵卿.呼吸内科学[M].北京:人民卫生出版社,1984.623.
  • 2王曾礼.内科学第五版[M].北京:人民卫生出版社,2000.141.
  • 3Maleux G, Nevens F, Wilmar-A, et al. Early and long-term clinical and radiological follow-up results of expanded-polytetrafluoroethylene-covered stent-grafts for transjugniar intrahepatic portosystemic shunt procedures[J]. Eur Radiol,2004,14(10) : 1842-1850.
  • 4Garcia N Jr, Mihas AA. Hepatic hydrothorax : pathophysiology, diagnosis, and management [ J ]. J Clin Gastroenterol, 2004,38( 1 ) : 52-58.
  • 5Pop CM, Gherasim RM, Dumitrascu DL, et al. Hydrothorax without ascites in liver cirrhosis[ J]. Rom J Gestroenterol, 2003,12(4) : 315-317.
  • 6Ong JP, Sands M, Younossi ZM. Transjugular intrahepatic portosystemic shunts (TIPS) : a decade later [ J ]. J Clin Gastroenterogy, 2001,301( 1 ) : 14-28.
  • 7Rossi P, Salvatori FM, Fanelli F. Polytetrafluoroethylene-covered nitinol stent-graft for transjugtflar intrahepatic portosystemic shunt creation : 3-year experience [ J ]. Radiology, 2004,231 (3) : 820-830.
  • 8Bhattacharya A, Mittal BR, Biswas T, et al. Radioisotope scintigraphy in the diagnosis of hepatic hydrothorax[J]. J Gastroenterol Hepatol,2001,16(3) :317-321.
  • 9Umino J, Tanaka E, Ichijoh T, et al. Hepatic hydrothorax in the absence of ascites diagnosed by intraperitoneal spraying of indocyanine green [ J ]. Intern Med, 2004,43 (4) : 283-288.
  • 10Miksad R, de Ledinghen V, McDougall C, et al. Hepatic hydrothorax associated with vitamin A toxicity[J]. J Clin Gastroenterol, 2002,34(3) :275-279.

共引文献14085

同被引文献19

  • 1杜昕,郑海英.肝硬化并发胸腔积液21例临床分析[J].中国煤炭工业医学杂志,2004,7(8):758-758. 被引量:1
  • 2Yasudo H, Ando T, Takeuchi M, et al. Systemlc lupus erythematosus complicated with liver cirrhosis in a patient with Papillon-Lef6vre syndrome[J]. Lupus, 2014, 23(14): 1523- 1527.
  • 3Bomhardier C,Gladman DD, Vrowitz MB, et al. Derivation of the SLEDAI. A disease activity index for lupus pantients. The committee on prognosis studies in SLE[J]. Arthritis Rheum, 1992, 35(6): 630-640.
  • 4Grover S, Rastogi A, Singh J, et al. Spectrum of histomorphologic findings in liver in patients with SLE: a review[J].Hepat Res Treat, 2014,2014:562979.
  • 5Abrahum S, Begum S, Isenberg D. Hepatic manifestations of autoimmune rheumatic disease[J]. Ann Rheum Dis, 2004, 63 (2) :123-129.
  • 6Cowling DC, Mackay IR, Taft LI. Lupoid hepatitis [J].Lancet, 1956, 271(6957) : 1323-1326.
  • 7Gibson T, Myers AR. Subclinical liver disease in systemic lupus erythematosus[J].J Rheumatol, 1981, 8(5) :762-759.
  • 8Vaiphei K, Bhatia A, Sinha SK. Liver pathology in collagen vascular disorders highlighting the vascular changes within portal tracts[J]. Ind J Pathol Microhiol, 2011, 54(1) :25-31.
  • 9Runyon BA, LaBrecque DR, Anuras S. The spectrum'0f liver disease in systemic lupus erythematosus: report 'of 33 histologically-proved cases and review of the literature[J].Am J Med, 1980,69(2) :187-194.
  • 10Lu MC, Li KJ, Hsieh SC, et al. Lupus-related advanced hver involvement as the initial presentation of systemic lupus erythematosus[J]. J Microbiol Immunol Infect, 2006, 39 (6) : 471-475.

引证文献2

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部